Skip to main content

Table 3 Classifier performance assessed via repeated 10-fold cross validation

From: Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis

Data sets

Treatment

Patient breakdown

Median AUROC(95 % CI)

Median specificity(95 % CI)

Median sensitivity(95 % CI)

Median precision(95 % CI)

Median likelihood ratio(95 % CI)

GSE12051, GSE19821, GSE58795, GSE33377infliximab

Infliximab

32 NR, 84 R

71 %**(60-81 %)

92 %(84-97 %)

31 %(16-50 %)

60 %(36-81 %)

3.94(1.78-8.7)

  1. Repeated 10-fold cross validation performance for a classifier trained on four whole blood infliximab data sets
  2. R, responder; NR, non-responder; CI, confidence interval. ** indicates AUROC p-value < 0.01
Back to article page

BMC Medical Genomics

ISSN: 1755-8794

Contact us